Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer.
Amgen and UCB Team Up with NASA
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis,
London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency
- Details
- Category: GlaxoSmithKline
London 2012 partner GlaxoSmithKline (GSK) signed a long-term agreement with the World Anti-Doping Agency (WADA) that will help the agency create early detection methods for medicines that have performance-enhancing potential in sport.
Novartis receives FDA approval for Arcapta(TM) Neohaler(TM)
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved once-daily Arcapta(TM) Neohaler(TM) (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema[1].
Pfizer and ChemRar to Explore Innovative Medical Research and Development Partnership in Russia
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center (ChemRar) have signed a Memorandum of Understanding (MoU) to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries.
Bayer advances research in the area of pulmonary hypertension
- Details
- Category: Bayer
Bayer HealthCare is working with the Ludwig Boltzmann Institute (LBI) for Lung Vascular Research in the research area of lung vascular diseases - especially pulmonary hypertension.
AstraZeneca and PTC Therapeutics announce strategic oncology drug discovery collaboration
- Details
- Category: AstraZeneca
AstraZeneca and PTC Therapeutics, Inc. (PTC) have entered into an exclusive research collaboration and license agreement for the application of PTC's proprietary GEMS™ technology (Gene Expression Modulation by Small-molecules) for the discovery and development of potential new therapies for cancer and other diseases for which there is a great unmet medical need.
More Pharma News ...
- Pfizer Files with the FDA for Review of Axitinib for Patients with Advanced Renal Cell Carcinoma
- Bristol-Myers Squibb to Expand Access to Reyataz® in sub-Saharan Africa and India
- Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control
- Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants
- Merck: Regulatory Update on Cladribine Tablets
- Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
- Boehringer Ingelheim and Ashoka announce a global partnership for "Making More Health"